Ritonavir is an HIV protease inhibitor with a molecular weight of 720.9 g/mol. It has a melting point of 120-122°C and purity of 99.4%. Ritonavir is a weak base with pH-dependent solubility and pKa values of 1.8 and 2.6. It is soluble in ethanol and DMSO but poorly soluble in water. Ritonavir should be stored between 5-30°C and can undergo thermal degradation starting at 80°C with complete decomposition at 200°C.
A Review On Pharmaceutical Preformulation Studies in Formulation and Development of New Drug Molecules - International Journal of Pharmaceutical Sciences and Research
Ritonavir is an HIV protease inhibitor with a molecular weight of 720.9 g/mol. It has a melting point of 120-122°C and purity of 99.4%. Ritonavir is a weak base with pH-dependent solubility and pKa values of 1.8 and 2.6. It is soluble in ethanol and DMSO but poorly soluble in water. Ritonavir should be stored between 5-30°C and can undergo thermal degradation starting at 80°C with complete decomposition at 200°C.
Ritonavir is an HIV protease inhibitor with a molecular weight of 720.9 g/mol. It has a melting point of 120-122°C and purity of 99.4%. Ritonavir is a weak base with pH-dependent solubility and pKa values of 1.8 and 2.6. It is soluble in ethanol and DMSO but poorly soluble in water. Ritonavir should be stored between 5-30°C and can undergo thermal degradation starting at 80°C with complete decomposition at 200°C.
Ritonavir is an HIV protease inhibitor with a molecular weight of 720.9 g/mol. It has a melting point of 120-122°C and purity of 99.4%. Ritonavir is a weak base with pH-dependent solubility and pKa values of 1.8 and 2.6. It is soluble in ethanol and DMSO but poorly soluble in water. Ritonavir should be stored between 5-30°C and can undergo thermal degradation starting at 80°C with complete decomposition at 200°C.
of Ritonavir • Ritonavir – A HIV protease inhibitors.
Molecular • 720.9 g/mol
Weight • Large, peptide-like molecule
Melting • 120- 122 ⁰C (Tiwari & Bonde, 2011)
Point
Purity • 99.4%, high purity (Chinnaiah et al., 2015)
LogP • 3.546 (DrugBank; Tiwari & Bonde, 2011)
• Ritonavir = weak-base drug with pH-dependent solubility Pka • Pka values = 1.8 and 2.6 (Law et al., 2001; Xu et al., 2017)
• Soluble in inorganic solvent like ethanol (5 mg/ml), DMSO
Solubility (15 mg/ml) • Poorly soluble in water .
• Store between 5° and 30°.
• Thermal degradation study (Gambhir et al., 2015) • drug started degrading at 80 °C Stability • major structural changes after exposure to thermal radiation at 100 °C • completely decomposed after 200 °C. References 1. Chinnaiah P, Lanka AR, Pamidi S, Govada PP, LNSR Jillella V. NEW VALIDATED RP-HPLC METHOD FOR IDENTIFICATION AND QUANTITATION OF PROCESS AND DEGRADATION RELATED IMPURITIES IN THE COMBINED DOSAGE TABLETS OF ATAZANAVIR AND RITONAVIR [Internet]. Vol. 2, Palavan Chinnaiah /J Compr Phar. 2015 [cited 2020 Nov 11]. Available from: www.jcponline.in 2. Ritonavir | 155213-67-5 [Internet]. [cited 2020 Nov 11]. Available from: https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0119429.htm 3. Tiwari RN, Bonde CG. LC, LC-MS/TOF and MSn studies for the separation, identification and characterization of degradation products of ritonavir. Anal Methods [Internet]. 2011 Jul [cited 2020 Nov 11];3(7):1674. Available from: http://xlink.rsc.org/?DOI=c1ay05140g 4. Xu H, Vela S, Shi Y, Marroum P, Gao P. In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance. Mol Pharm [Internet]. 2017 Nov 6 [cited 2020 Nov 11];14(11):3801–14. Available from: https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.7b00552 5. Law D, Krill SL, Schmitt EA, Fort JJ, Qiu Y, Wang W, et al. Physicochemical considerations in the preparation of amorphous ritonavir- poly(ethylene glycol) 8000 solid dispersions. J Pharm Sci [Internet]. 2001 Aug [cited 2020 Nov 11];90(8):1015–25. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022354916307869 6. Gambhir K, Singh P, Jangir DK, Mehrotra R. Thermal stability and hydration behavior of ritonavir sulfate: A vibrational spectroscopic approach. J Pharm Anal [Internet]. 2015 Dec 1 [cited 2020 Nov 11];5(6):348–55. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2095177915000519 7. (No Title) [Internet]. [cited 2020 Nov 11]. Available from: https://www.caymanchem.com/pdfs/13872.pdf
A Review On Pharmaceutical Preformulation Studies in Formulation and Development of New Drug Molecules - International Journal of Pharmaceutical Sciences and Research